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1. Introduction 
Charcot neuro-osteoarthropathy (CN) is most often seen in patients with diabetes although 
it has been associated with syringomyelia, tabes dorsalis, leprosy and hereditary sensory 
neuropathy. It is defined by painful or relatively painless bone and joint destruction and 
deformity in limbs that have lost sensory innervation, it commonly develops in the mid-foot 
but also in the forefoot and hind foot [1]. The estimated prevalence in diabetic population is 
between 0,1% and 7,5% [2]. Due to the rapid severe and irreversible foot deformity, 
recognition of acute CN is extremely important. The clinical presentation between type 1 
and type 2 diabetes is not different, but on epidemiological level the age of presentation of 
an acute CN is at an earlier age and longer disease duration [3]. 
2. Risk factors and pathophysiology 
Trauma, previous ulcer, infection or surgery of the foot are predisposing factors for CN as 
well as neuropathy, osteopenia and renal impairment, although the exact pathogenesis is 
still unknown [3].  
In peripheral blood monocytes isolated from Charcot patients, the osteoclast formation was 
significant increased compared to diabetic patients and healthy controls. The osteoclastic 
resorption increased after addition of receptor activator of NFB ligand (RANKL). So in the 
acute stage of CN, the osteoclast activity is increased probably by increased expression of 
receptor activator of NFB ligand (RANKL) via release of proinflammatory cytokines as 
TNF-alfa [4,5]. Central role in this process of local inflammation is trauma. Patients with 
diabetes do not notice most traumas due to the peripheral neuropathy. Trauma will induce 
pro-inflammatory cytokines like TNF-alfa and RANKL will be expressed. Due to loss in 
pain perception by the distal neuropathy, the TNF-alfa release will persist and the RANKL 
pathway is persistently stimulated [6].  
3. Clinical presentation 
The acute stage is characterized by unilateral erythema and oedema of the affected foot. The 
temperature is at least 2° Celsius higher than the non-affected foot, which can be measured 
with an infrared skin thermometer. Mostly the mid foot is affected, followed by the fore foot 
and hind foot. 
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The differential diagnosis of a red, hot swollen foot is: severe infection (osteomyelitis) in 
case of a concurrent foot ulcer, cellulitis, bone fracture, gout or septic arthritis. Most difficult 
is to differentiate between an acute CN and osteomyelitis if a foot ulcer is present. Clinical 
directions in favour for osteomyelitis are a positive probe to the bone test and radiological 
abnormalities in relation to the ulcer, that is mostly located on pressure points like 
metatarsal heads or rocker-bottom. Radiological abnormalities in favour of CN are 
radiological abnormalities in the mid foot. The chronic not active Charcot foot is 
characterized with joint deformity, and or (sub) luxation of the metatarsals leading to 
rocker-bottom. These deformities cause elevated plantar pressure leading to abundant callus 
formation and an increased risk for foot ulcers. 
 
Fig. 1. Red hot swollen foot. 
4. Diagnosis 
Although in a very early stage of an acute CN the plain X-ray can be false negative, the 
initial screening tool for an acute CN is still a plain X-ray in three directions: dorsoplantar, 
lateral and pronated oblique). The radiological description is according to the five D’s: bone 
density, joint distention, bony debris, joint disorganization and dislocation of the joint [2].  
The density of the bone is usually normal, except in elderly or type 1 diabetic patients. Large 
joint effusions cause distention. The most frequent dislocation is the tarsometatarsal 
subluxation: Lisfranc’s dislocation. Less frequent are dislocations of the talonavicular joint 
(Chopart) or subtalar or intertarsal joints. Sella and Barrette introduced five stage of Charcot 
deformity based on clinical and radiological features [7].  
Stage 0: clinical stage of warm red swollen foot 
Stage 1: localized osteoporosis, subchondral cysts, erossions and diastasis 
Stage 2: joint subluxations 
Stage 3: joint dislocations  
Stage 4: sclerosis fusion  
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Therefore has a plain X-ray an important role in diagnosis and follow up of CN. 
 
Fig. 2. Dislocation in tarsometatarsal joints: Lisfranc’s dislocation 
Magnetic resonance imaging (MRI) is the second step in the diagnosis the CN foot. 
Especially in Sella and Barrette stage 0, the early phase of the acute CN, MRI will show 
subchondral bone marrow oedema and or microfractures. The images should included T1 
and short tau inversion recovery (STIR) or T2 fat saturated sequences. The use of computed 
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tomography (CT) is not well investigated. The five D’s as mentioned above can be adapted 
to CT images. Bone scintigraphy (technetium) is the most often used nuclear method. Focal 
hyperperfusion and or focal bony uptake are seen on the scintigraphy but are not specific 
for CN. Also in osteomyelitis these characteristics are seen.  
 
Fig. 3. Dislocation in Lisfranc, talonavicular joint (Chopart) and ankle fork 
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5. Treatment 
Acute CN 
The current standard treatment is off-loading the affected foot with a total contact cast or a 
prefabricated walking cast. Off-loading will prevent extensive bone damage, which can lead 
to sub-luxation and dislocation leading to severe foot deformity. Off-loading is continued 
until clinical signs of activity (temperature differential) are resolved and there is no longer 
evidence on X-ray of continuing bone destruction. Median time of off-loading treatment is 9 
(7-12) months [8].  
Chronic CN 
If the CN is inactive, the patients have to be rehabilitated. This process has to be gradually to 
prevent recurrence for CN leading to further bone destruction. Patients need orthopaedic 
shoes during this process and the walking distance is extended slowly, first with two 
crutches followed with one and finally without.    
Operative orthopaedic treatment is indicated for chronic recurrent ulcers on pressure points 
like rocker-bottom or joint instability. Operative procedures in acute CN are strongly not 
recommended: the bone structure is too instable for internal of external fixation and every 
orthopaedic intervention is a risk factor for increase in activity of CN. Osteotomy is possible 
in inactive CN in combination with bony prominence that cause recurrent ulcers. Obvious, 
arterial insufficiency is ruled out or has been treated before elective surgery.  
6. Additional treatment with bisphosphonates? 
To shorten the time of CN activity, intervention at the level of osteoclasts and or osteoblasts 
might be useful. Because bisphosphonates induce osteoclast apoptosis [9], several trials with 
bisphosphonates were performed. In the acute setting of CN the use of oral alendronate 70 
mg once weekly on top of standard care (total contact cast immobilisation) was studied in a 
small double blind placebo controlled trial [10]. After 6 months, a reduction in bone 
turnover markers was demonstrated, but not in skin temperature. In another double blind 
placebo controlled trial studied the additional effect of one single infusion of intravenous 
pamidronate in patients with acute CN [11]. The intervention group had a faster fall in 
temperature of the affected foot at four weeks, a greater reduction in bone turnover markers 
and significant reduction in Charcot related symptoms during the study. In one not-
randomized study confirmed the effect of pamidronate on temperature reduction and fall in 
bone turnover markers in acute CN [12]. However, all three studies did not report reduction 
in immobilisation time, as a clinical marker for the activity of CN. 
Risk of bisphosphonates 
Minor side effects of oral bisphosphonates are gastrointestinal symptoms, hypocalcaemia, 
skin reactions, acute phase reactions like malaise or fever or skin. These side effects have 
biological plausibility and causality has been proven. 
No causality is proven for some severe adverse effects of bisphosphonates: osteonecrosis of 
jaw, atypical hip fractures, possible oesophagus cancer, atrial fibrillation and 
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musculoskeletal pain. But clinical correlations were seen and reported in literature, for 
example osteonecrosis of the jaw [13]. Risk factors for developing osteonecrosis of the jaw 
are intravenous administration of bisphosphonates, history of inflammatory dental disease, 
glucocorticoids use and long duration of bisphosphonates use [14]. Of note, all severe events 
were seen if the bisphosphonates were used for several years. Furthermore, the reported 
data are conflicting and sometimes incomplete.  
In conclusion, there is no indication for bisphosphonates in the treatment of an acute CN if 
no data are known about reduction is immobilisation time.   
7. Possible candidates for additional treatment in acute CN 
Strontium ranelate 
Another potential intervention is strontium ranelate that is successfully used in the 
treatment of osteoporosis [15-17]. This drug has a direct inhibitive action on both osteoclast 
activity and differentiation. In addition, strontium ranelate stimulates the osteoprogenitor 
cells and collagen in osteoblasts [18,19]. Recent evidence has shown that strontium ranelate 
induced osteoprotegerin-  (OPG) mRNA expression and suppressed RANKL mRNA in 
human osteoblasts [20]. Furthermore strontium ranelate induced osteoblast replication and 
differentiation [20]. Strontium ranelate is to date it has not yet been used as treatment in the 
acute stage of CN. 
Denosumab 
Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear 
factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and 
activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its 
unique actions, denosumab may be useful in the treatment of osteoporosis and bone 
metastatic disease. Some clinical trials have been performed and show favourable results 
[21,22]. In acute CN, no studies have been performed so far.  
8. Summary 
Charcot neuro-osteoarthropathy is most often seen in patients with diabetes and is 
characterized as red, hot swollen foot. In the presence of a foot ulcer, the differential 
diagnosis with osteomyelitis is very difficult. In the early stage of acute CN, X ray can be 
false negative in contrast to MRI or CT. The latter investigations can be useful to 
differentiate between osteomyelitis and acute CN. The treatment of acute CN is offloading 
in plaster cast until the active CN is clinical and radiological inactive.  
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